These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 31932333)
1. Price transparency is a step towards sustainable access in middle income countries. Cernuschi T; Gilchrist S; Hajizada A; Malhame M; Mariat S; Widmyer G BMJ; 2020 Jan; 368():l5375. PubMed ID: 31932333 [No Abstract] [Full Text] [Related]
2. Improving access to vaccines through tiered pricing. Berkley S Lancet; 2014 Jun; 383(9936):2265-7. PubMed ID: 24636625 [No Abstract] [Full Text] [Related]
3. [HIV therapy: tenofir DF is available in 68 developing countries at production costs price]. Med Klin (Munich); 2003 Jul; 98(7):XV-XVI. PubMed ID: 12945544 [No Abstract] [Full Text] [Related]
4. Can affordability and innovation coexist for medicines? Colbert A; Rintoul A; Simão M; Hill S; Swaminathan S BMJ; 2020 Jan; 368():l7058. PubMed ID: 31932276 [No Abstract] [Full Text] [Related]
5. Drug company-sponsored patient assistance programs: a viable safety net? Choudhry NK; Lee JL; Agnew-Blais J; Corcoran C; Shrank WH Health Aff (Millwood); 2009; 28(3):827-34. PubMed ID: 19414893 [TBL] [Abstract][Full Text] [Related]
6. Differential pricing for pharmaceuticals: reconciling access, R&D and patents. Danzon PM; Towse A Int J Health Care Finance Econ; 2003 Sep; 3(3):183-205. PubMed ID: 14625999 [TBL] [Abstract][Full Text] [Related]
7. The GO License: only part of the solution. Batson A; Milstien JB Health Aff (Millwood); 2008; 27(1):140-2. PubMed ID: 18180489 [TBL] [Abstract][Full Text] [Related]
8. Drug companies agree to cut price of HPV vaccine to developing countries to increase accessibility. Gulland A BMJ; 2013 May; 346():f3025. PubMed ID: 23667128 [No Abstract] [Full Text] [Related]
9. Perspective of vaccine manufacturers on financing pediatric and adolescent vaccines in the United States. Shen AK; Rodewald LE; Birkhead GS Pediatrics; 2009 Dec; 124 Suppl 5():S540-7. PubMed ID: 19948586 [TBL] [Abstract][Full Text] [Related]
10. Pharma Dynamics: targeting safe, effective and affordable medication for South Africa and neighbouring countries. Cardiovasc J Afr; 2009; 20(1):85. PubMed ID: 19287824 [No Abstract] [Full Text] [Related]
11. Defining the concept of fair pricing for medicines. Moon S; Mariat S; Kamae I; Pedersen HB BMJ; 2020 Jan; 368():l4726. PubMed ID: 31932334 [No Abstract] [Full Text] [Related]
12. Ethics and AIDS drugs. Dowell W Time; 1999 Jul; 154(2):49. PubMed ID: 10538646 [No Abstract] [Full Text] [Related]
13. [Risk sharing methods in middle income countries]. Inotai A; Kaló Z Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986 [TBL] [Abstract][Full Text] [Related]
14. Using strategic price negotiations to contain costs and expand access to medicines in China. Si L; Xu L; Chen M; Jan S BMJ Glob Health; 2020; 5(1):e002256. PubMed ID: 32133184 [No Abstract] [Full Text] [Related]
15. Market-based licensing for HPV vaccines in developing countries. Outterson K; Kesselheim AS Health Aff (Millwood); 2008; 27(1):130-9. PubMed ID: 18180488 [TBL] [Abstract][Full Text] [Related]
16. No money, no meds. Mabry M Newsweek; 1999 Jul; 134(2):32-3. PubMed ID: 10538648 [No Abstract] [Full Text] [Related]
18. Improving global health: the need to think 'outside the box'! Benatar SR Monash Bioeth Rev; 2003 Apr; 22(2):69-72. PubMed ID: 15069959 [No Abstract] [Full Text] [Related]
19. Merck, Bristol-Myers Squibb announce major price reductions for poorest countries: major access progress but questions remain. James JS AIDS Treat News; 2001 Feb; (361):5-7. PubMed ID: 12765151 [TBL] [Abstract][Full Text] [Related]
20. Industry-Led Access-To-Medicines Initiatives In Low- And Middle-Income Countries: Strategies And Evidence. Rockers PC; Wirtz VJ; Umeh CA; Swamy PM; Laing RO Health Aff (Millwood); 2017 Apr; 36(4):706-713. PubMed ID: 28373337 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]